Home
Products
Learn
About
Pricing
Log In

What are you looking for?

Home
Pricing
Compare AU

Compare UMAX vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Betashares S&P 500 Yield Maximiser Complex ETF

ASX

Buy

Buy

Global X S&P Biotech ETF

ASX

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares S&P 500 Yield Maximiser Complex ETF (UMAX) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

UMAX

CURE

Popularity

Low

Low

Pearlers invested

45

78

Median incremental investment

$993.50

$640.11

Median investment frequency

Monthly

Monthly

Median total investment

$2,315.52

$1,274.70

Average age group

> 35

> 35


Key Summary

UMAX

CURE

Strategy

UMAX.AX was created on 2014-09-17 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. UMAX.AX aims to generate attractive quarterly income and reduce the volatility of portfolio returns by implementing an equity income investment strategy over a portfolio of stocks comprising the S&P 500 Index. UMAX.AX does not aim to track an index.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

SPX US 04/17/25 C5840 (0 %)

SPX US 04/17/25 C5870 (0 %)

ISHARES CORE S&P 500 ETF (97.87 %)

Natera Inc (2.70 %)

Vertex Pharmaceuticals Inc (2.67 %)

Alnylam Pharmaceuticals Inc (2.64 %)

Top 3 industries

Other (99.94 %)

Communication Services (0.06 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (99.40 %)

Switzerland (0.28 %)

Netherlands (0.13 %)

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.79 %

0.45 %


Key Summary

UMAX

CURE

Issuer

BetaShares

Global X

Tracking index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.79 %

0.45 %

Price

$24.12

$42.49

Size

$248.027 million

$28.994 million

10Y return

41.47 %

N/A

Annual distribution yield (5Y)

6.08 %

4.24 %

Market

ASX

ASX

First listed date

19/09/2014

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

UMAX

CURE

Popularity

Low

Low

Pearlers invested

45

78

Median incremental investment

$993.50

$640.11

Median investment frequency

Monthly

Monthly

Median total investment

$2,315.52

$1,274.70

Average age group

> 35

> 35


Pros and Cons

UMAX

CURE

Pros

  • Higher exposure to US market

  • Higher price growth

  • Higher distribution yield

  • Lower management fee

Cons

  • Higher management fee

  • Lower exposure to US market

  • Lower price growth

  • Lower distribution yield

UMAX

CURE

Higher exposure to US market

Lower exposure to US market

Higher management fee

Lower management fee

Higher price growth

Lower price growth

Higher distribution yield

Lower distribution yield